化学療法の世界市場2019-2025

• 英文タイトル:Global Chemotherapy Sale, Insights Market Research Report 2019-2025

Global Chemotherapy Sale, Insights Market Research Report 2019-2025「化学療法の世界市場2019-2025」(市場規模、市場予測)調査レポートです。• レポートコード:STR-DC011
• 出版社/出版日:Straits Research / 2019年11月28日
• レポート形態:英文、PDF、145ページ
• 納品方法:Eメール(受注後2-3日)
• 産業分類:製薬
• 販売価格(消費税別)
  Single User(1名様用、印刷不可)¥459,000 (USD4,250)▷ お問い合わせ
  Multi User(5名様用)¥610,200 (USD5,650)▷ お問い合わせ
  Enterprise Price(法人閲覧用)¥783,000 (USD7,250)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
当調査レポートでは、化学療法の世界市場について調査・分析し、調査手法、市場概要、薬物種類別(アルキル化剤、代謝拮抗剤、抗腫瘍抗生物質、トポイソメラーゼ阻害剤、有糸分裂阻害剤、その他)分析、疾患別(白血病、リンパ腫、乳がん、卵巣がん、肺がん、骨髄腫、肉腫、その他)分析、投与経路別(経口、静脈内)分析、エンドユーザー別(病院、研究所、その他)分析、地域別分析、企業概要などを含め次の構成でお届け致します。

・イントロダクション
・調査手法
・市場概要
・化学療法の世界市場:薬物種類別(アルキル化剤、代謝拮抗剤、抗腫瘍抗生物質、トポイソメラーゼ阻害剤、有糸分裂阻害剤、その他)
・化学療法の世界市場:疾患別(白血病、リンパ腫、乳がん、卵巣がん、肺がん、骨髄腫、肉腫、その他)
・化学療法の世界市場:投与経路別(経口、静脈内)
・化学療法の世界市場:エンドユーザー別(病院、研究所、その他)
・化学療法の世界市場:地域別
・企業概要

This report studies the High Purity Aluminum market status and outlook of global and major regions, from angles of manufacturers, regions, product types and end industries; this report analyzes the top manufacturers in global and major regions, and splits the High Purity Aluminum market by product type and applications/end industries.

The High Purity Aluminum market was valued at USD xx Million in 2018. It is projected to reach USD xx Million by 2025, growing at a CAGR of xx% from 2018. Europe, North America, and Asia-Pacific are still the main markets of High Purity Aluminum. High Purity Aluminum has low penetration in India, the Middle East and Africa, which makes these markets have great market potential. Market players are responding to new opportunities by expanding their global presence and product offerings. On the one hand, High Purity Aluminum manufacturers are dedicated to lowering their manufacturing cost; on the other hand, they try to provide more qualified products to customers. Besides, they are trying to broaden the applications of High Purity Aluminum.

This report includes estimations of the market size in terms of value (USD million). Both, top-down and bottom-up approaches have been used to estimate and validate the size of the High Purity Aluminum market and to estimate the size of various other dependent submarkets in the overall market. This research study involved the extensive usage of both primary and secondary data sources.

The research process involved the study of various factors affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry, and market risks, opportunities, market barriers and challenges.

Main content of the study are:
To define, segment, and forecast the size of the High Purity Aluminum market with respect to type, application and region
To understand market conditions, company ranking, market structure, growth drivers by report
To historical and forecast the data of the market segments with respect to United States, EU, CIS, China, India, Japan, SEA, South America, Middle East, Oceania and the Rest of the World
To provide detailed information about the crucial factors that are influencing the growth of the market (drivers, restraints, opportunities, and challenges)
To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders

The major players in global market include
Joinworld
HYDRO
Chinalco Baotou Aluminum
KMAC
Rusal
Sumitomo
C-KOE Metals
Columbia Specialty Metals
Geographically, this report is segmented into several key Regions, with production, consumption, revenue, market share and growth rate of High Purity Aluminum in these regions, from 2013 to 2024 (forecast), covering
North America
EU
CIS
China
India
Japan
SEA
South America
Middle East
Oceania
Row

On the basis of product, the High Purity Aluminum market is primarily split into
4N Category
4N5 Category
5N and 5N+ Category
On the basis on the end users/applications, this report covers
Electronic Industry
Chemical Industry
High Purity Alloy
Other Applications

Chapter 1, to describe High Purity Aluminum Introduction, product types, technology, industrial chain, market risk, industry policy;

Chapter 2, to analyze of High Purity Aluminum industry raw material and manufacturing cost;

Chapter 3, to analyze the major manufacturers of High Purity Aluminum, with capacity, production, revenue, and price of High Purity Aluminum, from 2014 to 2019;

Chapter 4, to show the global market by regions, with capacity, production, revenue and market share of High Purity Aluminum, for each region, from 2014 to 2019;

Chapter 5, to show the global market by regions, with sales, import, export and market share of High Purity Aluminum, for each region, from 2014 to 2019;

Chapter 6 and 7, to analyze the market by countries, by type and by application with sales, revenue and market share by key countries in these regions;

Chapter 8, to analyze the major manufacturers of High Purity Aluminum, with basic information, and data of High Purity Aluminum, from 2014 to 2019;

Chapter 9 and 10, to describe High Purity Aluminum sales channel, distributors and competitive products

Chapter 11, to analyze new project investment feasibility

Chapter 12, High Purity Aluminum market forecast, by regions, type and application, with production, sales and revenue, from 2020 to 2025;

レポート目次

TABLE OF CONTENTS
1 Introduction
1.1 Market Definition
1.2 Market Scope
2 Research Methodology
2.1 Primary Research
2.2 Research Methodology
2.3 Assumptions & Exclusions
2.4 Secondary Data Sources
3 Market Overview
3.1 Report Segmentation & Scope
3.2 Value Chain Analysis: Chemotherapy Market
3.3 Key Market Trends
3.3.1 Drivers
3.3.2 Restraints
3.3.3 Opportunities
3.4 Porter’s Five Forces Analysis
3.4.1 Bargaining Power of Suppliers
3.4.2 Bargaining Power of Buyers
3.4.3 Threat of Substitution
3.4.4 Threat of New Entrants
3.4.5 Competitive Rivalry
3.5 Market Share Analysis
3.6 Chemotherapy Market, By Drugs, 2017 and 2018
3.7 Pipeline Analysis
3.8 Cost Effective Analysis
4 By Drug type Overview
4.1 Introduction
4.1.1 Market Size & Forecast (Value)
4.2 Alkylating Agents
4.2.1 Mustard Gas Derivatives
4.2.2. Ethylenimines
4.2.3 Alkyl Sulfonates
4.2.4 Hydrazines
4.2.5 Triazines
4.2.6 Others
4.3 Antimetabolites
4.4 Anti-Tumor Antibiotics
4.4.1 Anthracyclines
4.4.2 Chromomycin
4.5 Topoisomerase Inhibitors
4.5.1 Topoisomerase I Inhibitors
4.5.2 Topoisomerase Ii Inhibitors
4.6 Mitotic Inhibitors
4.7 Others
5 By Indication Overview
5.1 Introduction
5.1.1 Market Size & Forecast (Value)
5.2 Leukemia
5.3 Lymphoma
5.4 Breast Cancer
5.5 Ovarian Cancer
5.6 Lung Cancer
5.7 Myeloma
5.8 Sarcoma
5.9 Others
6 By Route of Drug Administration Overview
6.1 Introduction
6.1.1 Market Size & Forecast (Value)
6.2 Oral
6.3 Intravenous
7. By End User Type
7.1 Introduction
7.1.1 Market Size & Forecast (Value)
7.2 Hospitals
7.3 Research Institutes
7.4 Others
8 Regional Overview
8.1 Introduction
8.1.1 Market Size & Forecast (Value)
8.2 America
8.2.1 North America
8.2.1.1 U.S.
8.2.1.1.1 By Drug type
8.2.1.1.2 By Indication
8.2.1.1.3 By Route of Drug Administration
8.2.1.1.4 By End Users
8.2.1.2 Canada
8.2.1.2.1 By Drug type
8.2.1.2.2 By Indication
8.2.1.2.3 By Route of Drug Administration
8.2.1.2.4 By End Users
8.2.1.3 Mexico
8.2.1.3.1 By Drug type
8.2.1.3.2 By Indication
8.2.1.3.3 By Route of Drug Administration
8.2.1.3.4 By End Users
8.2.2 Latin America
8.2.2.1 By Drug type
8.2.2.2 By Indication
8.2.2.3 By Route of Drug Administration
8.2.2.4 By End Users
8.3 Europe
8.3.1 Market Size & Forecast (Value)
8.3.2 Germany
8.3.2.1. By Drug type
8.3.2.2 By Indication
8.3.2.3 By Route of Drug Administration
8.3.2.4 By End Users
8.3.3 France
8.3.3.1 By Drug type
8.3.3.2 By Indication
8.3.3.3 By Route of Drug Administration
8.3.3.4 By End Users
8.3. 4 U.K
8.3.4.1 By Drug type
8.3.4.2 By Indication
8.3.4.3 By Route of Drug Administration
8.3.4.4 By End Users
8.3.5 Italy
8.3.5.1 By Drug type
8.3.5.2 By Indication
8.3.5.3 By Route of Drug Administration
8.3.5.4 By End Users
8.3.6 Spain
8.3.6.1 By Drug type
8.3.6.2 By Indication
8.3.6.3 By Route of Drug Administration
8.3.6.4 By End Users
8.3.7 Rest of Europe
8.3.7.1 By Drug type
8.3.7.2 By Indication
8.3.7.3 By Route of Drug Administration
8.3.7.4 By End Users
8.4 Asia Pacific
8.4.1 Market Size & Forecast (Value)
8.4.2 Japan
8.4.2.1 By Drug type
8.3.2.2 By Indication
8.4.2.3 By Route of Drug Administration
8.4.2.4 By End Users
8.4.3 China
8.4.3.1 By Drug type
8.4.3.2 By Indication
8.4.3.3 By Route of Drug Administration
8.4.3.4 By End Users
8.4.4 Australia
8.4.4.1 By Drug type
8.4.4.2 By Indication
8.4.4.3 By Route of Drug Administration
8.4.4.4 By End Users
8.4.5 India
8.4.5.1 By Drug type
8.4.5.2 By Indication
8.4.5.3 By Route of Drug Administration
8.5.5.4 By End Users
8.4.6 South Korea
8.4.6.1 By Drug type
8.4.6.2 By Indication
8.4.6.3 By Route of Drug Administration
8.4.6.4 By End Users
8.4.7 Rest of Asia-Pacific
8.4.7.1 By Drug type
8.4.7.2 By Indication
8.4.7.3 By Route of Drug Administration
8.4.7.4 By End Users
8.5 Middle East & Africa
8.5.1 Market Size & Forecast (Value)
8.5.2 Saudi Arabia
8.5.2.1 By Drug type
8.5.2.2 By Indication
8.5.2.3 By Route of Drug Administration
8.5.2.4 By End Users
8.5.3 South Africa
8.5.3.1 By Drug type
8.5.3.2 By Indication
8.5.3.3 By Route of Drug Administration
8.5.3.4 By End Users
8.5.4 Kwait
8.5.4.1 By Drug type
8.5.4.2 By Indication
8.5.4.3 By Route of Drug Administration
8.5.4.4 By End Users
8.5.5 Rest of Middle East & Africa
8.5.5.1 By Drug type
8.5.5.2 By Indication
8.5.5.3 By Route of Drug Administration
8.5.5.4 By End Users
9 Company Profile
9.1 Delacroix-Chevalier
9.1.1 Company Overview
9.1.2 Financial Performance
9.1.3 Recent Developments
9.1.4 Drug Portfolio
9.2 FSSB surgical needles GmbH
9.2.1 Company Overview
9.2.2 Financial Performance
9.2.3 Recent Developments
9.2.4 Product Portfolio
9.3 Becton, Dickinson, and Company
9.3.1 Company Overview
9.3.2 Financial Performance
9.3.3 Recent Developments
9.3.4 Product Portfolio
9.4 B. Braun Melsungen AG
9.4.1 Company Overview
9.4.2 Financial Performance
9.4.3 Recent Developments
9.4.4 Product Portfolio
9.5 Sheffield Ltd.
9.5.1 Company Overview
9.5.2 Financial Performance
9.5.3 Recent Developments
9.5.4 Product Portfolio
9.6 CP Medical, Inc.
9.6.1 Company Overview
9.6.2 Financial Performance
9.6.3 Recent Developments
9.6.4 Product Portfolio
9.7 Ethicon Inc.
9.7.1 Company Overview
9.7.2 Financial Performance
9.7.3 Recent Developments
9.7.4 Product Portfolio
9.8 KLS Martin Group
9.8.1 Company Overview
9.8.2 Financial Performance
9.8.3 Recent Developments
9.8.4 Product Portfolio
9.9 Sklar Surgical Instruments
9.9.1 Company Overview
9.9.2 Financial Performance
9.9.3 Recent Developments
9.9.4 Product Portfolio
9.10 Wexler Surgical
9.10.1 Company Overview
9.10.2 Financial Performance
9.10.3 Recent Developments
9.10.4 Product Portfolio
9.11 Quality Needles Pvt. Ltd.
9.11.1 Company Overview
9.11.2 Financial Performance
9.11.3 Recent Developments
9.11.4 Product Portfolio
9.12 Rumex International Corporation Ltd.
9.12.1 Company Overview
9.12.2 Financial Performance
9.12.3 Recent Developments
9.12.4 Product Portfolio
9.13 Teleflex Incorporated
9.13.1 Company Overview
9.13.2 Financial Performance
9.13.3 Recent Developments
9.13.4 Product Portfolio
9.14 Medline Industries, Inc.
9.14.1 Company Overview
9.14.2 Financial Performance
9.14.3 Recent Developments
9.14.4 Product Portfolio
9.14 Surgins surgical Ltd.
9.14.1 Company Overview
9.14.2 Financial Performance
9.14.3 Recent Developments
9.14.4 Product Portfolio
9.14 Surtex Instruments Ltd.
9.14.1 Company Overview
9.14.2 Financial Performance
9.14.3 Recent Developments
9.14.4 Product Portfolio
9.15 Cardivon Surgical Inc.
9.15.1 Company Overview
9.15.2 Financial Performance
9.15.3 Recent Developments
9.15.4 Product Portfolio
9.16 Symmetry Surgical Inc.
9.16.1 Company Overview
9.16.2 Financial Performance
9.16.3 Recent Developments
9.16.4 Product Portfolio

TABLE 1 GLOBAL CHEMOTHERAPY MARKET SHARE, BY DRUG TYPE, 2016-2026 ($MILLION)
TABLE 2 ROUND BODIED NEEDLES CHEMOTHERAPY MARKET SHARE, BY REGION, 2016-2026, ($ MILLION)
TABLE 3 CUTTING NEEDLES CHEMOTHERAPY MARKET SHARE, BY REGION, 2016-2026, ($ MILLION)
TABLE 4 GLOBAL CHEMOTHERAPY MARKET SHARE, BY INDICATION, 2016-2026 ($MILLION)
TABLE 5 SINGLE USE CHEMOTHERAPY MARKET SHARE, BY REGION, 2016-2026, ($ MILLION)
TABLE 6 MULTIPLE USE CHEMOTHERAPY MARKET SHARE, BY REGION, 2016-2026, ($ MILLION)
TABLE 7 GLOBAL CHEMOTHERAPY MARKET SHARE, BY ROUTE OF DRUG ADMINISTRATION, 2016-2026 ($MILLION)
TABLE 8 OPEN HEART SURGERY CHEMOTHERAPY MARKET SHARE, BY REGION, 2016-2026, ($ MILLION)
TABLE 9 CARDIAC VALVE PROCEDURES CHEMOTHERAPY MARKET SHARE, BY REGION, 2016-2026, ($ MILLION)
TABLE 10 GLOBAL CHEMOTHERAPY MARKET SHARE, BY END USRES TYPE 2016-2026 ($MILLION)
TABLE 11 HOSPITALS CHEMOTHERAPY MARKET SHARE, BY REGION, 2016-2026, ($ MILLION)
TABLE 12 AMBULATORY SURGICAL CENTERS CHEMOTHERAPY MARKET SHARE, BY REGION, 2016-2026, ($ MILLION)
TABLE 13 AMERICA CHEMOTHERAPY MARKET SHARE VALUE, BY COUNTRY, 2016-2026 ($MILLION)
TABLE 14 AMERICA CHEMOTHERAPY MARKET SHARE VALUE, BY DRUG TYPE, 2016-2026 ($MILLION)
TABLE 15 AMERICA CHEMOTHERAPY MARKET SHARE VALUE, BY ROUTE OF DRUG ADMINISTRATION, 2016-2026 ($MILLION)
TABLE 16 U.S. CHEMOTHERAPY MARKET SHARE, BY DRUG TYPE, 2016-2026 ($MILLION)
TABLE 17 U.S. CHEMOTHERAPY MARKET SHARE, BY ROUTE OF DRUG ADMINISTRATION, 2016-2026 ($MILLION)
TABLE 18 CANADA CHEMOTHERAPY MARKET SHARE, BY DRUG TYPE, 2016-2026 ($MILLION)
TABLE 19 CANADA CHEMOTHERAPY MARKET SHARE, BY ROUTE OF DRUG ADMINISTRATION, 2016-2026 ($MILLION)
TABLE 20 MEXICO CHEMOTHERAPY MARKET SHARE, BY DRUG TYPE, 2016-2026 ($MILLION)
TABLE 21 MEXICO CHEMOTHERAPY MARKET SHARE, BY ROUTE OF DRUG ADMINISTRATION, 2016-2026 ($MILLION)
TABLE 22 LATIN AMERICA CHEMOTHERAPY MARKET SHARE, BY DRUG TYPE, 2016-2026 ($MILLION)
TABLE 23 LATIN AMERICA CHEMOTHERAPY MARKET SHARE, BY ROUTE OF DRUG ADMINISTRATION, 2016-2026 ($MILLION)
TABLE 24 EUROPE CHEMOTHERAPY MARKET SHARE VALUE, BY COUNTRY, 2016-2026 ($MILLION)
TABLE 25 EUROPE CHEMOTHERAPY MARKET SHARE, BY DRUG TYPE, 2016-2026 ($MILLION)
TABLE 26 EUROPE CHEMOTHERAPY MARKET SHARE, BY ROUTE OF DRUG ADMINISTRATION, 2016-2026 ($MILLION)
TABLE 27 GERMANY CHEMOTHERAPY MARKET SHARE, BY DRUG TYPE, 2016-2026 ($MILLION)
TABLE 28 GERMANY CHEMOTHERAPY MARKET SHARE, BY ROUTE OF DRUG ADMINISTRATION, 2016-2026 ($MILLION)
TABLE 29 FRANCE CHEMOTHERAPY MARKET SHARE, BY DRUG TYPE, 2016-2026 ($MILLION)
TABLE 30 FRANCE CHEMOTHERAPY MARKET SHARE, BY ROUTE OF DRUG ADMINISTRATION, 2016-2026 ($MILLION)
TABLE 31 UK CHEMOTHERAPY MARKET SHARE, BY DRUG TYPE, 2016-2026 ($MILLION)
TABLE 32 UK CHEMOTHERAPY MARKET SHARE, BY ROUTE OF DRUG ADMINISTRATION, 2016-2026 ($MILLION)
TABLE 33 ITALY CHEMOTHERAPY MARKET SHARE, BY DRUG TYPE, 2016-2026 ($MILLION)
TABLE 34 ITALY CHEMOTHERAPY MARKET SHARE, BY ROUTE OF DRUG ADMINISTRATION, 2016-2026 ($MILLION)
TABLE 35 SPAIN CHEMOTHERAPY MARKET SHARE, BY DRUG TYPE, 2016-2026 ($MILLION)
TABLE 36 SPAIN CHEMOTHERAPY MARKET SHARE, BY ROUTE OF DRUG ADMINISTRATION, 2016-2026 ($MILLION)
TABLE 37 REST OF EUROPE CHEMOTHERAPY MARKET SHARE, BY DRUG TYPE, 2016-2026 ($MILLION)
TABLE 38 REST OF EUROPE CHEMOTHERAPY MARKET SHARE, BY ROUTE OF DRUG ADMINISTRATION, 2016-2026 ($MILLION)
TABLE 39 ASIA-PACIFIC CHEMOTHERAPY MARKET SHARE VALUE, BY COUNTRY, 2016-2026 ($MILLION)
TABLE 40 ASIA-PACIFIC CHEMOTHERAPY MARKET SHARE, BY DRUG TYPE, 2016-2026 ($MILLION)
TABLE 41 ASIA-PACIFIC CHEMOTHERAPY MARKET SHARE, BY ROUTE OF DRUG ADMINISTRATION, 2016-2026 ($MILLION)
TABLE 42 JAPAN CHEMOTHERAPY MARKET SHARE, BY DRUG TYPE, 2016-2026 ($MILLION)
TABLE 43 JAPAN CHEMOTHERAPY MARKET SHARE, BY ROUTE OF DRUG ADMINISTRATION, 2016-2026 ($MILLION)
TABLE 44 CHINA CHEMOTHERAPY MARKET SHARE, BY DRUG TYPE, 2016-2026 ($MILLION)
TABLE 45 CHINA CHEMOTHERAPY MARKET SHARE, BY ROUTE OF DRUG ADMINISTRATION, 2016-2026 ($MILLION)
TABLE 46 AUSTRALIA CHEMOTHERAPY MARKET SHARE, BY DRUG TYPE, 2016-2026 ($MILLION)
TABLE 47 AUSTRALIA CHEMOTHERAPY MARKET SHARE, BY ROUTE OF DRUG ADMINISTRATION, 2016-2026 ($MILLION)
TABLE 48 INDIA CHEMOTHERAPY MARKET SHARE, BY DRUG TYPE, 2016-2026 ($MILLION)
TABLE 49 INDIA CHEMOTHERAPY MARKET SHARE, BY ROUTE OF DRUG ADMINISTRATION, 2016-2026 ($MILLION)
TABLE 50 SOUTH KOREA CHEMOTHERAPY MARKET SHARE, BY DRUG TYPE, 2016-2026 ($MILLION)
TABLE 51 SOUTH KOREA CHEMOTHERAPY MARKET SHARE, BY ROUTE OF DRUG ADMINISTRATION, 2016-2026 ($MILLION)
TABLE 52 REST OF ASIA-PACIFIC CHEMOTHERAPY MARKET SHARE, BY DRUG TYPE, 2016-2026 ($MILLION)
TABLE 53 REST OF ASIA-PACIFIC CHEMOTHERAPY MARKET SHARE, BY ROUTE OF DRUG ADMINISTRATION, 2016-2026 ($MILLION)
TABLE 54 LAMEA CHEMOTHERAPY MARKET SHARE VALUE, BY COUNTRY, 2016-2026 ($MILLION)
TABLE 55 LAMEA CHEMOTHERAPY MARKET SHARE, BY DRUG TYPE, 2016-2026 ($MILLION)
TABLE 56 LAMEA CHEMOTHERAPY MARKET SHARE, BY ROUTE OF DRUG ADMINISTRATION, 2016-2026 ($MILLION)
TABLE 57 SAUDI ARABIA CHEMOTHERAPY MARKET SHARE, BY DRUG TYPE, 2016-2026 ($MILLION)
TABLE 58 SAUDI ARABIA CHEMOTHERAPY MARKET SHARE, BY DRUG TYPE, 2016-2026 ($MILLION)
TABLE 59 SAUDI ARABIA CHEMOTHERAPY MARKET SHARE, BY ROUTE OF DRUG ADMINISTRATION, 2016-2026 ($MILLION)
TABLE 60 SAUDI ARABIA CHEMOTHERAPY MARKET SHARE, BY ROUTE OF DRUG ADMINISTRATION, 2016-2026 ($MILLION)
TABLE 61 SOUTH AFRICA CHEMOTHERAPY MARKET SHARE, BY DRUG TYPE, 2016-2026 ($MILLION)
TABLE 62 SOUTH AFRICA CHEMOTHERAPY MARKET SHARE, BY DRUG TYPE, 2016-2026 ($MILLION)
TABLE 63 SOUTH AFRICA CHEMOTHERAPY MARKET SHARE, BY ROUTE OF DRUG ADMINISTRATION, 2016-2026 ($MILLION)
TABLE 64 SOUTH AFRICA CHEMOTHERAPY MARKET SHARE, BY ROUTE OF DRUG ADMINISTRATION, 2016-2026 ($MILLION)
TABLE 65 SOUTH AFRICA CHEMOTHERAPY MARKET SHARE, BY END USER, 2016-2026 ($MILLION)
TABLE 66 SOUTH AFRICA CHEMOTHERAPY MARKET SHARE, BY END USER, 2016-2026 ($MILLION)
TABLE 67 BRAZIL CHEMOTHERAPY MARKET SHARE, BY DRUG TYPE, 2016-2026 ($MILLION)
TABLE 68 BRAZIL CHEMOTHERAPY MARKET SHARE, BY DRUG TYPE, 2016-2026 ($MILLION)
TABLE 69 BRAZIL CHEMOTHERAPY MARKET SHARE, BY ROUTE OF DRUG ADMINISTRATION, 2016-2026 ($MILLION)
TABLE 70 BRAZIL CHEMOTHERAPY MARKET SHARE, BY ROUTE OF DRUG ADMINISTRATION, 2016-2026 ($MILLION)
TABLE 71 REST OF LAMEA CHEMOTHERAPY MARKET SHARE, BY DRUG TYPE, 2016-2026 ($MILLION)
TABLE 72 REST OF LAMEA CHEMOTHERAPY MARKET SHARE, BY DRUG TYPE, 2016-2026 ($MILLION)
TABLE 73 REST OF LAMEA CHEMOTHERAPY MARKET SHARE, BY ROUTE OF DRUG ADMINISTRATION, 2016-2026 ($MILLION)
TABLE 74 REST OF LAMEA CHEMOTHERAPY MARKET SHARE, BY ROUTE OF DRUG ADMINISTRATION, 2016-2026 ($MILLION)
LIST OF FIGURES
FIGURE 1 GLOBAL CHEMOTHERAPY MARKET OVERVIEW
FIGURE 2 VALUE CHAIN ANALYSIS
FIGURE 3 BARGAINING POWER OF SUPPLIERS
FIGURE 4 BARGAINING POWER OF BUYERS
FIGURE 5 THREAT OF SUBSTITUTES
FIGURE 6 THREAT OF NEW ENTRANTS
FIGURE 7 COMPETITIVE RIVALRY
FIGURE 8 CHEMOTHERAPY MARKET SHARE ANALYSIS, 2016
FIGURE 9 GLOBAL CARDIOVASCULAR NEEDLE 2016-2026
FIGURE 10 U.S. CHEMOTHERAPY MARKET SHARE, 2016-2026 ($MILLION)
FIGURE 11 CANADA CHEMOTHERAPY MARKET SHARE, 2016-2026 ($MILLION)
FIGURE 12 MEXICO CHEMOTHERAPY MARKET SHARE, 2016-2026 ($MILLION)
FIGURE 13 GERMANY CHEMOTHERAPY MARKET SHARE, 2016-2026 ($MILLION)
FIGURE 14 FRANCE CHEMOTHERAPY MARKET SHARE, 2016-2026 ($MILLION)
FIGURE 15 UK CHEMOTHERAPY MARKET SHARE, 2016-2026 ($MILLION)
FIGURE 16 ITALY CHEMOTHERAPY MARKET SHARE, 2016-2026 ($MILLION)
FIGURE 17 SPAIN CHEMOTHERAPY MARKET SHARE, 2016-2026 ($MILLION)
FIGURE 18 REST OF EUROPE CHEMOTHERAPY MARKET SHARE, 2016-2026 ($MILLION)
FIGURE 19 JAPAN CHEMOTHERAPY MARKET SHARE, 2016-2026 ($MILLION)
FIGURE 20 CHINA CHEMOTHERAPY MARKET SHARE, 2016-2026 ($MILLION)
FIGURE 21 AUSTRALIA CHEMOTHERAPY MARKET SHARE, 2016-2026 ($MILLION)
FIGURE 22 INDIA CHEMOTHERAPY MARKET SHARE, 2016-2026 ($MILLION)
FIGURE 23 SOUTH KOREA CHEMOTHERAPY MARKET SHARE, 2016-2026 ($MILLION)
FIGURE 24 REST OF ASIA-PACIFIC CHEMOTHERAPY MARKET SHARE, 2016-2026 ($MILLION)
FIGURE 25 SAUDI ARABIA CHEMOTHERAPY MARKET SHARE, 2016-2026 ($MILLION)
FIGURE 26 SOUTH AFRICA CHEMOTHERAPY MARKET SHARE, 2016-2026 ($MILLION)
FIGURE 27 BRAZIL CHEMOTHERAPY MARKET SHARE, 2016-2026 ($MILLION)
FIGURE 28 REST OF LAMEA CHEMOTHERAPY MARKET SHARE, 2016-2026 ($MILLION)
FIGURE 29 DELACROIX-CHEVALIER: REVENUE ANALYSIS, ($ MILLION)
FIGURE 30 DELACROIX-CHEVALIER: SEGMENT REVENUE 2017 (%)




• 英文レポート名:Global Chemotherapy Sale, Insights Market Research Report 2019-2025
• 日本語訳:化学療法の世界市場2019-2025
• レポートコード:STR-DC011お問い合わせ(見積依頼・ご注文・質問)